Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

116.70 -0.12 (-0.10%)
Streaming Delayed Price Updated: 2:24 PM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
4 Stocks to Buy for a Potential “Summer Panic”
Luke Lango predicts a major event on May 7 will trigger a flood of cash – as much as $7 trillion – to rush back into U.S. stocks. It’s a catalyst that could change the entire market dynamic and create... 
Via InvestorPlace
Exposures COVID-19
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment. 
Via Benzinga
Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets
Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Earnings Scheduled For May 1, 2025
Via Benzinga
14 Analysts Have This To Say About Biogen
Via Benzinga
How Is The Market Feeling About Biogen?
Via Benzinga
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar
The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Biogen Earnings: What To Look For From BIIB
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Exposures Political
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion
Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer's treatment. 
Via Benzinga
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
What 14 Analyst Ratings Have To Say About Biogen
Via Benzinga
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen
Eli Lilly's donanemab faces a setback as EMA's CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases. 
Via Benzinga
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company. 
Via The Motley Fool
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option. 
Via Benzinga
Indexes Swimming In Red Ink On Recession Fears
Stocks are looking to extend last week's losses, as recession fears grip Wall Street. 
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Economy
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs and limited benefit. Stakeholders can submit feedback until March 27, 2025,... 
Via Benzinga
Stocks Plummet As Trade Partners Retaliate Against Tariffs
Stocks are free falling as President Donald Trump's tariffs against Mexico, Canada, and China take effect. 
Via Talk Markets
Topics Government Stocks / Equities World Trade
Exposures Political Tariff
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now trades at $140.49. This was partly driven by its softer quarterly results and... 
Via StockStory
Synchronicity: Denying The Unexplainable
Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph? 
Via Talk Markets
Topics Stocks / Equities
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing... 
Via Benzinga
Biogen Stock Is Mutating Into a Value Play
Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X 
Via MarketBeat
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.